Memantine (Ebixa) ( DrugBank: Memantine )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00353665 (ClinicalTrials.gov) | July 2005 | 18/7/2006 | Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS) | Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Memantine (Ebixa);Drug: riluzole;Drug: Placebo | University of Lisbon | H. Lundbeck A/S | Completed | 20 Years | 75 Years | Both | 63 | Phase 2/Phase 3 | Portugal |